About cAMP-dependent protein kinase catalytic subunit beta
cAMP-dependent protein kinase catalytic subunit beta (PRKACB) is a protein
from Homo sapiens identified by UniProt accession
P22694, 351 residues long.
MolForge cross-references it against 0 known binders and
115 disease associations.
Target properties
| Protein name | cAMP-dependent protein kinase catalytic subunit beta |
| UniProt accession | P22694 |
| Gene | PRKACB |
| Organism | Homo sapiens |
| Length | 351 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (115)
Diseases linked to this target (Open Targets).
- cardioacrofacial dysplasia 2 · score 0.71
- Ellis Van Creveld syndrome · score 0.37
- bone density · score 0.30
- urate measurement · score 0.30
- body fat percentage · score 0.30
- platelet count · score 0.26
- lung adenocarcinoma · score 0.26
- cutaneous melanoma · score 0.20
- genetic disorder · score 0.18
- fat body mass · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P22694-F1 | alphafold | PREDICTED | 95.20 | — |
Amino-acid sequence (351 residues)
MGNAATAKKG SEVESVKEFL AKAKEDFLKK WENPTQNNAG LEDFERKKTL GTGSFGRVML VKHKATEQYY AMKILDKQKV VKLKQIEHTL NEKRILQAVN FPFLVRLEYA FKDNSNLYMV MEYVPGGEMF SHLRRIGRFS EPHARFYAAQ IVLTFEYLHS LDLIYRDLKP ENLLIDHQGY IQVTDFGFAK RVKGRTWTLC GTPEYLAPEI ILSKGYNKAV DWWALGVLIY EMAAGYPPFF ADQPIQIYEK IVSGKVRFPS HFSSDLKDLL RNLLQVDLTK RFGNLKNGVS DIKTHKWFAT TDWIAIYQRK VEAPFIPKFR GSGDTSNFDD YEEEDIRVSI TEKCAKEFGE F
Explore cAMP-dependent protein kinase catalytic subunit beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets